Evidence map›Paper›PMID 30211685›Full record

ReviewDiagnostic and interventional radiology (Ankara, Turkey)2018

Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience.

Kareem N Rayn, Graham R Hale, Jonathan B Bloom, Samuel A Gold, Filipe L F Carvalho, Sherif Mehralivand, Marcin Czarniecki, Bradford J Wood, Maria J Merino, Peter Choyke and 3 more

Open access · greenAbstract readReview
In one paragraph

Review in Diagnostic and interventional radiology (Ankara, Turkey), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. [Management of isolated urinary bladder amyloidsis].Urologie (Heidelberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kareem N RaynUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Graham R HaleUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jonathan B BloomUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Samuel A GoldUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Filipe L F CarvalhoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Urology MedStar Georgetown University Hospital, Washington, DC, USA.
Sherif MehralivandUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Marcin CzarnieckiMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Bradford J WoodCenter for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Maria J MerinoLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Peter ChoykeMolecular Imaging Program National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Barış TürkbeyMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Peter A PintoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Piyush K AgarwalUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USNational Cancer Institute · US

Funding

Molecular Targeted Photoimmunotherapy for Bladder CancerZIABC011458 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AGARWAL, PIYUSH · 2012 to 2019
$3.5M
6 · The paper itself

Abstract

purposeIn the era of multiparametric magnetic resonance imaging (mpMRI) of the prostate gland, incidental findings are occasionally discovered on imaging. We aimed to report our experience of detecting incidental bladder cancers on mpMRI of the prostate in asymptomatic patients without irritative voiding symptoms or microscopic or gross hematuria.

methodsA retrospective review was performed on a prospectively maintained database of all men who underwent prostate mpMRI at our institution from 2012 to 2018. Patients who were found to have incidental bladder lesions were identified and baseline demographics, imaging and histopathologic data were recorded. All patients with incidental bladder lesion detection on mpMRI, not attributable to extension of prostate cancer, underwent cystoscopy in addition to a biopsy and/or transurethral resection of bladder tumor (TURBT) if warranted on cystoscopy.

resultsThere were 3147 prostate mpMRIs performed during this period and 25 cases (0.8%) of incidental bladder lesions were detected. These patients did not have any presenting symptoms such as gross or microscopic hematuria to prompt bladder lesion workup. The largest diameter of incidentally discovered bladder lesions ranged from 0.4 cm to 1.7 cm. Of the 25 cases of incidental bladder lesions, five were suspected to be due to prostate cancer invasion into the bladder. Only two of these five patients underwent biopsy, which confirmed prostate adenocarcinoma in both cases. Of the 20 patients without suspected prostate cancer invasion of the bladder, four had no suspicious lesions on cystoscopy to warrant a biopsy. The remaining 16 patients had bladder lesions seen on cystoscopy and underwent a biopsy and/or TURBT. Three of these patients had benign features on pathology (urachal remnant, amyloidosis and inflammation) and the remaining 13 had stage Ta urothelial carcinoma. Seven of these patients had low-grade Ta tumors and six had high-grade Ta tumors. All patients were treated with standard management of TURBT with or without intravesical BCG. There have been no reported cases of recurrence or progression in any of the patients in our cohort at the median follow-up of 26 months (interquartile range,19-40 months).

conclusionmpMRI of the prostate may yield incidental findings, such as small bladder tumors. Awareness of the possibility of incidental bladder lesions is important as 65% of lesions reported in the bladder, not attributable to extension of prostate cancer, proved to be bladder cancer. This may allow for early intervention for asymptomatic patients with undetected bladder cancer prior to disease progression.

Indexed as

Administration, IntravesicalAgedAsymptomatic DiseasesAwarenessCystoscopyHumansIncidental FindingsMagnetic Resonance ImagingMaleMiddle AgedNeoplasm InvasivenessProspective StudiesProstateProstatic NeoplasmsRetrospective StudiesSurvival Rate

Identifiers

PMID30211685
PMCPMC6135055
OpenAlexW2891646681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.